ALS Genetics: Gains, Losses, and Implications for Future Therapies - PubMed

ALS Genetics: Gains, Losses, and Implications for Future Therapies - PubMed

ALS Genetics: Gains, Losses, and Implications for Future Therapies

Garam Kim 1, Olivia Gautier 1, Eduardo Tassoni-Tsuchida 2, X Rosa Ma 3, Aaron D Gitler 4

Affiliations 

• PMID: 32931756
 
• DOI: 10.1016/j.neuron.2020.08.022

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder caused by the loss of motor neurons from the brain and spinal cord. The ALS community has made remarkable strides over three decades by identifying novel familial mutations, generating animal models, elucidating molecular mechanisms, and ultimately developing promising new therapeutic approaches. Some of these approaches reduce the expression of mutant genes and are in human clinical trials, highlighting the need to carefully consider the normal functions of these genes and potential contribution of gene loss-of-function to ALS. Here, we highlight known loss-of-function mechanisms underlying ALS, potential consequences of lowering levels of gene products, and the need to consider both gain and loss of function to develop safe and effective therapeutic strategies.

Keywords: ALS; C9ORF72; FUS; OPTN; SOD1; TARDBP; TBK1; TDP-43; gain of function; loss of function.

Copyright © 2020 Elsevier Inc. All rights reserved.

Conflict of interest statement

Declaration of Interests A.D.G. has served as a consultant for Aquinnah Pharmaceuticals, Prevail Therapeutics, and Third Rock Ventures and is a scientific founder of Maze Therapeutics.

Similar articles

• Oligogenic inheritance of optineurin (OPTN) and C9ORF72 mutations in ALS highlights localisation of OPTN in the TDP-43-negative inclusions of C9ORF72-ALS.

  Bury JJ, Highley JR, Cooper-Knock J, Goodall EF, Higginbottom A, McDermott CJ, Ince PG, Shaw PJ, Kirby J.Neuropathology. 2016 Apr;36(2):125-34. doi: 10.1111/neup.12240. Epub 2015 Aug 24.PMID: 26303227
• The genetics of amyotrophic lateral sclerosis: current insights.

  Alsultan AA, Waller R, Heath PR, Kirby J.Degener Neurol Neuromuscul Dis. 2016 May 13;6:49-64. doi: 10.2147/DNND.S84956. eCollection 2016.PMID: 30050368 Free PMC article. Review.
• Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways.

  Blokhuis AM, Koppers M, Groen EJN, van den Heuvel DMA, Dini Modigliani S, Anink JJ, Fumoto K, van Diggelen F, Snelting A, Sodaar P, Verheijen BM, Demmers JAA, Veldink JH, Aronica E, Bozzoni I, den Hertog J, van den Berg LH, Pasterkamp RJ.Acta Neuropathol. 2016 Aug;132(2):175-196. doi: 10.1007/s00401-016-1575-8. Epub 2016 May 10.PMID: 27164932 Free PMC article.
• FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis.

  Kabashi E, Bercier V, Lissouba A, Liao M, Brustein E, Rouleau GA, Drapeau P.PLoS Genet. 2011 Aug;7(8):e1002214. doi: 10.1371/journal.pgen.1002214. Epub 2011 Aug 4.PMID: 21829392 Free PMC article.
• From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis.

  Alrafiah AR.In Vivo. 2018 Sep-Oct;32(5):983-998. doi: 10.21873/invivo.11339.PMID: 30150420 Free PMC article. Review.